Zacks Investment Research on MSN
MRK stock gains after CHMP backs Keytruda combo for bladder cancer
Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
SurvivorNet on MSN
Inlexzo: A new option for bladder cancer patients when BCG immunotherapy stops working
If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your options, talk to a urologist or genitourinary oncologist about whether Inlexzo ...
May 14 () - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.) PR Newswire TOKYO and NEW YORK, April 20, 2026 TOKYO and NEW YORK, ...
Results of two phase 3 studies — IMvigor011 and DYNAMIC-III — presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2025 suggest that circulating tumor DNA (ctDNA) could help ...
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer ...
"The data from the EV-304 trial take us another step closer to bringing perioperative enfortumab vedotin plus pembrolizumab to patients with muscle-invasive bladder cancer regardless of cisplatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results